NEW NANOTHERAPY RESEARCH FOR INFLAMMATORY BOWEL DISEASES

eleven european partners five european countries
four year project six million project
      THE NEW DEAL CONCEPT COULD REVOLUTIONIZE IBD THERAPIES FOR THE GREAT BENEFIT OF PATIENTS AND EUROPEAN HEALTHCARE SYSTEMS.Dr. Fabrice NAVARRO, New Deal Project Coordinator

      THE PROJECT GOALS

      The NEW DEAL project aims to develop a highly selective and local therapy with an improved efficacy and safety profile for IBD patients. This treatment might be an alternative to the existing therapies.

      molecular target therapy

      Design and validate a radically improved IBD therapy that specifically targets JAK1 / JAK3 inhibition by means of siRNA and RNAi interference

      inflammatory bowel disease

      Develop advanced technologies for delivering
      siJAK1 / siJAK3 locally       to the inflamed gut

      health general practitioners

      Promote the clinical translation and the future industrial transfer of this new clinical product for IBD therapy

      THE PROJECT PARTNERS

      commissariat energie atomique
      european research services
      helmholtz center for infection research
      nanoimmunotech
      eurofins amatsigroup
      prodigest
      idibaps
      mayoly spindler
      inserm
      boyds
      scienseed
      sparks and co

      From 2017 to 2018